Exact Sciences is touting new results for its Oncodetect cancer test, which demonstrate its “strong performance” in detecting disease and predicting recurrence.
That’s according to Brian Baranick, general manager of precision oncology at the Madison-based diagnostics company.
“We’re thrilled to bring our MRD solution to the rapidly growing molecular residual disease market, helping more pat...
Please log in to access subscriber content.
If you don't have a subscription, click
here for a WisPolitics free trial and to view the different subscription options.
